NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in it: Adding Italian translations) |
(Changed label, description and/or aliases in es: Adding Spanish translations) |
||
| label / es | label / es | ||
NEUROTERA.: Para la comercialización de nuevos agentes terapéuticos contra las comorbilidades oculares y cerebrales asociadas a la paramiloidosis | |||
Revision as of 08:19, 21 January 2022
Project Q2907213 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
891,221.0 Euro
0 references
1,136,308.0 Euro
0 references
78.43 percent
0 references
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references